Streetbeat News

Stock Prices

SOLUSD

Solana (SOL) has risen by 4.11% in the past 24 hours to $172.88, continuing its positive trend with a 2.0% gain over the past week. Despite a 10% drop in trading volume, its market cap stands at $79.56 billion, ranking #5.

Portfolio Pulse from Benzinga Insights

June 05, 2024 | 3:00 pm

GAUZ

Gauzy Ltd (NASDAQ:GAUZ) is set to IPO on June 6th on the NASDAQ exchange with shares priced between $17.00 and $19.00. The insider lock-up period will last 180 days, ending on December 3, 2024.

Portfolio Pulse from Benzinga Insights

June 05, 2024 | 3:00 pm

PVH

PVH Corp (NYSE:PVH), the parent company of Calvin Klein and Tommy Hilfiger, reported better-than-expected Q1 earnings, leading to a 2% rise in its stock price. Analysts from BMO Capital Markets, JPMorgan, Goldman Sachs, and Wedbush provided positive feedback, with some raising their price targets. Despite a 10% revenue decline, PVH's gross margins and adjusted earnings surpassed expectations.

Portfolio Pulse from Priya Nigam

June 05, 2024 | 3:00 pm

FSI

Flexible Solutions International (FSI) is expanding into the food and nutrition supplement markets, including injectable drugs like GLP-1 for weight loss. The company is also continuing its development of biodegradable polymers and environmentally safe water and energy conservation technologies.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 2:59 pm

FSI

Flexible Solutions International shares were halted on a circuit breaker due to a significant upward movement, with the stock now up 23.1%.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 2:59 pm

ATAI

CMPS

MNMD

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) shares are trading lower after the FDA panel rejected the approval of MDMA therapy for PTSD. Other psychedelic stocks, including ATAI Life Sciences N.V (NASDAQ:ATAI) and COMPASS Pathways Plc (NASDAQ:CMPS), are also down. The FDA panel expressed concerns about the study designs submitted by Lykos Therapeutics.

Portfolio Pulse from Erica Kollmann

June 05, 2024 | 2:58 pm

AVIR

Atea Pharmaceuticals Inc (NASDAQ:AVIR) announced promising Phase 2 data for its hepatitis C virus (HCV) therapy, bemnifosbuvir. The study showed a 97% sustained virologic response rate at 12 weeks post-treatment and a 100% response rate in genotype 3 patients. The therapy was well tolerated with no severe adverse events. The company plans to present these findings at the EASL Congress.

Portfolio Pulse from Vandana Singh

June 05, 2024 | 2:55 pm

BA

Boeing's Starliner capsule has successfully launched on its first crewed mission to the International Space Station, marking a significant milestone for the company in the space exploration sector.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 2:53 pm

BA

Elon Musk extended his best wishes to Boeing for the first crewed test flight of their Starliner spacecraft to the ISS. The mission, crucial for Boeing's entry into the commercial spaceflight sector, faced multiple delays but was successfully launched on June 5.

Portfolio Pulse from Benzinga Neuro

June 05, 2024 | 2:53 pm

LULU

Lululemon Athletica (NASDAQ:LULU) shares are trading lower ahead of the company's earnings release for the 2024 fiscal-year first quarter. Analysts expect EPS of $2.39 and revenue of $2.2 billion. Last quarter, Lululemon beat expectations with an adjusted EPS of $5.29 and revenue of $3.20 billion.

Portfolio Pulse from Dylan Berman

June 05, 2024 | 2:52 pm